New Lung health package at Lifescan

January 9, 2015

EarlyCDT-Lung has been widely available in the US for a number of years and is now available in the UK through a number of different providers. This month we would like to look at Lifescan and explore what they have to offer in helping assess your lung health.

Lifescan (http://www.lifescanuk.org/) have provided specialist health checks to over 70,000 people in the UK as part of Spire Healthcare which is a leading provider of healthcare with 39 hospitals throughout the UK. Lifescan aim to check for the early signs of heart disease, lung cancer, colon cancer and other serious illnesses before any symptoms are experienced.

EarlyCDT-Lung is available as part of Lifescan’s ‘Lung Check’ package.  This package is available to people over the age of 45 and uses 2 different types of diagnostic method (x-ray and CT scan). The choice of test is dependent upon certain factors such as age and risk profile.

If patients have a Moderate or High EarlyCDT-Lung test result, they will be offered a follow up CT scan, free of charge.

A lung function and lung age test is also provided for everyone having a Lung Check as it helps to establish how well your lungs are currently working.  It simply involves breathing long and hard into a special device, which will monitor how well your lungs are functioning and estimates how ‘old’ your lungs are compared to your actual age.

EarlyCDT-Lung is also available in the UK through many different providers.

EarlyCDT®-Lung is a simple blood test which is ordered by your Doctor to aid in the risk assessment and early detection of lung cancer.

EarlyCDT-Lung has been developed so that individuals at moderate and high risk of lung cancer can benefit from increasing the chances of lung cancer can being detected at the earliest possible stages, when treatment can be most successful.


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept